These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
11. Bendamustine-120 plus rituximab therapy for relapsed or refractory follicular lymphoma: a multicenter phase II study. Sakai R; Ohmachi K; Sano F; Watanabe R; Takahashi H; Takasaki H; Tanaka M; Hattori Y; Kimura H; Takimoto M; Tachibana T; Tanaka E; Ishii Y; Ishiyama Y; Hagihara M; Miyazaki K; Yamamoto K; Tomita N; Ando K Ann Hematol; 2019 Sep; 98(9):2131-2138. PubMed ID: 31286196 [TBL] [Abstract][Full Text] [Related]
12. Idelalisib or placebo in combination with bendamustine and rituximab in patients with relapsed or refractory chronic lymphocytic leukaemia: interim results from a phase 3, randomised, double-blind, placebo-controlled trial. Zelenetz AD; Barrientos JC; Brown JR; Coiffier B; Delgado J; Egyed M; Ghia P; Illés Á; Jurczak W; Marlton P; Montillo M; Morschhauser F; Pristupa AS; Robak T; Sharman JP; Simpson D; Smolej L; Tausch E; Adewoye AH; Dreiling LK; Kim Y; Stilgenbauer S; Hillmen P Lancet Oncol; 2017 Mar; 18(3):297-311. PubMed ID: 28139405 [TBL] [Abstract][Full Text] [Related]
13. The PARP Inhibitor Veliparib Can Be Safely Added to Bendamustine and Rituximab and Has Preliminary Evidence of Activity in B-Cell Lymphoma. Soumerai JD; Zelenetz AD; Moskowitz CH; Palomba ML; Hamlin PA; Noy A; Straus DJ; Moskowitz AJ; Younes A; Matasar MJ; Horwitz SM; Portlock CS; Konner JA; Gounder MM; Hyman DM; Voss MH; Fury MG; Gajria D; Carvajal RD; Ho AL; Beumer JH; Kiesel B; Zhang Z; Chen A; Little RF; Jarjies C; Dang TO; France F; Mishra N; Gerecitano JF Clin Cancer Res; 2017 Aug; 23(15):4119-4126. PubMed ID: 28314788 [No Abstract] [Full Text] [Related]
14. Venetoclax-Rituximab in Relapsed or Refractory Chronic Lymphocytic Leukemia. Seymour JF; Kipps TJ; Eichhorst B; Hillmen P; D'Rozario J; Assouline S; Owen C; Gerecitano J; Robak T; De la Serna J; Jaeger U; Cartron G; Montillo M; Humerickhouse R; Punnoose EA; Li Y; Boyer M; Humphrey K; Mobasher M; Kater AP N Engl J Med; 2018 Mar; 378(12):1107-1120. PubMed ID: 29562156 [TBL] [Abstract][Full Text] [Related]
15. Rituximab plus bendamustine or chlorambucil for chronic lymphocytic leukemia: primary analysis of the randomized, open-label MABLE study. Michallet AS; Aktan M; Hiddemann W; Ilhan O; Johansson P; Laribi K; Meddeb B; Moreno C; Raposo J; Schuh A; Ünal A; Widenius T; Bernhardt A; Kellershohn K; Messeri D; Osborne S; Leblond V Haematologica; 2018 Apr; 103(4):698-706. PubMed ID: 29419437 [TBL] [Abstract][Full Text] [Related]
16. Multicenter, Open-Label, Phase II Study of Bendamustine and Rituximab Followed by 90-Yttrium (Y) Ibritumomab Tiuxetan for Untreated Follicular Lymphoma (Fol-BRITe). Lansigan F; Costa CA; Zaki BI; Yen SP; Winer ES; Ryan H; Findley D; Metzler SR; Shaw L; Toaso B; MacKenzie TA; Chen Y; Beaven AW Clin Cancer Res; 2019 Oct; 25(20):6073-6079. PubMed ID: 31243122 [TBL] [Abstract][Full Text] [Related]
17. Current Treatment Options in Cold Agglutinin Disease: B-Cell Directed or Complement Directed Therapy? Berentsen S; Tjønnfjord GE Transfus Med Rev; 2022 Oct; 36(4):181-187. PubMed ID: 36127205 [TBL] [Abstract][Full Text] [Related]
18. How I manage patients with cold agglutinin disease. Berentsen S Br J Haematol; 2018 May; 181(3):320-330. PubMed ID: 29363757 [TBL] [Abstract][Full Text] [Related]
19. Rituximab, bendamustine, and low-dose cytarabine as induction therapy in elderly patients with mantle cell lymphoma: a multicentre, phase 2 trial from Fondazione Italiana Linfomi. Visco C; Chiappella A; Nassi L; Patti C; Ferrero S; Barbero D; Evangelista A; Spina M; Molinari A; Rigacci L; Tani M; Rocco AD; Pinotti G; Fabbri A; Zambello R; Finotto S; Gotti M; Carella AM; Salvi F; Pileri SA; Ladetto M; Ciccone G; Gaidano G; Ruggeri M; Martelli M; Vitolo U Lancet Haematol; 2017 Jan; 4(1):e15-e23. PubMed ID: 27927586 [TBL] [Abstract][Full Text] [Related]
20. [Alleviated anemia by bendamustine in cold agglutinin disease associated with small lymphocytic lymphoma]. Kuno M; Inoue A; Aimoto M; Nakao T; Kameda K; Yoshida M; Kanashima H; Hirai M; Yamane T Rinsho Ketsueki; 2015 Feb; 56(2):204-9. PubMed ID: 25765801 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]